

Elisabeth M Messmer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7802955/publications.pdf>

Version: 2024-02-01

47
papers

3,460
citations

201385

27
h-index

253896

43
g-index

53
all docs

53
docs citations

53
times ranked

2854
citing authors

#	ARTICLE	IF	CITATIONS
1	Pathophysiology of dry eye disease and novel therapeutic targets. <i>Experimental Eye Research</i> , 2022, 217, 108944.	1.2	12
2	Inflammation in Glaucoma: From the back to the front of the eye, and beyond. <i>Progress in Retinal and Eye Research</i> , 2021, 83, 100916.	7.3	183
3	Effect of IPL in Patients with Meibomian Gland Dysfunction. <i>Klinische Monatsblätter Fur Augenheilkunde</i> , 2021, 238, 893-898.	0.3	3
4	The Enduring Experience in Dry Eye Diagnosis: A Non-Interventional Study Comparing the Experiences of Patients Living With and Without Sjögren's Syndrome. <i>Ophthalmology and Therapy</i> , 2021, 10, 321-335.	1.0	0
5	Funktionelle Sehschärfe beim Trockenen Auge. <i>Spektrum Der Augenheilkunde</i> , 2021, 35, 143-149.	0.2	0
6	The ocular microbiome and microbiota and their effects on ocular surface pathophysiology and disorders. <i>Survey of Ophthalmology</i> , 2021, 66, 907-925.	1.7	56
7	Histological Corneal Alterations in Keratoconus After Crosslinking—Expansion of Findings. <i>Cornea</i> , 2020, 39, 333-341.	0.9	10
8	Defining Dry Eye from a Clinical Perspective. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9271.	1.8	118
9	TFOS European Ambassador meeting: Unmet needs and future scientific and clinical solutions for ocular surface diseases. <i>Ocular Surface</i> , 2020, 18, 936-962.	2.2	11
10	Penetrating keratoplasty after complicated small incision lenticule extraction a case report. <i>American Journal of Ophthalmology Case Reports</i> , 2020, 19, 100730.	0.4	0
11	Defining the needs and preferences of patients with dry eye disease. <i>BMJ Open Ophthalmology</i> , 2019, 4, e000315.	0.8	9
12	Comparing the needs and preferences of patients with moderate and severe dry eye symptoms across four countries. <i>BMJ Open Ophthalmology</i> , 2019, 4, e000360.	0.8	11
13	Reconsidering the central role of mucins in dry eye and ocular surface diseases. <i>Progress in Retinal and Eye Research</i> , 2019, 71, 68-87.	7.3	78
14	ADenoVirus Initiative Study in Epidemiology (ADVISE)—results of a multicenter epidemiology study in Germany. <i>Graefes Archive for Clinical and Experimental Ophthalmology</i> , 2019, 257, 249-251.	1.0	7
15	Efficacy and safety of 0.1% ciclosporin A cationic emulsion in dry eye disease: a pooled analysis of two double-masked, randomised, vehicle-controlled phase III clinical studies. <i>British Journal of Ophthalmology</i> , 2019, 103, 125-131.	2.1	35
16	Controlled Adverse Environment Chambers in Dry Eye Research. <i>Current Eye Research</i> , 2018, 43, 445-450.	0.7	20
17	Neurotrophic keratopathy. <i>Progress in Retinal and Eye Research</i> , 2018, 66, 107-131.	7.3	250
18	Clinical impact of inflammation in dry eye disease: proceedings of the <sc>ODISSEY</sc> group meeting. <i>Acta Ophthalmologica</i> , 2018, 96, 111-119.	0.6	100

#	ARTICLE	IF	CITATIONS
19	Emerging strategies for the diagnosis and treatment of meibomian gland dysfunction: Proceedings of the OCEAN group meeting. <i>Ocular Surface</i> , 2017, 15, 179-192.	2.2	107
20	The role of systemic and topical fatty acids for dry eye treatment. <i>Progress in Retinal and Eye Research</i> , 2017, 61, 23-34.	7.3	40
21	A Randomized Study of the Efficacy and Safety of 0.1% Cyclosporine a Cationic Emulsion in Treatment of Moderate to Severe Dry Eye. <i>European Journal of Ophthalmology</i> , 2017, 27, 520-530.	0.7	65
22	Visual acuity and quality of life in dry eye disease: Proceedings of the OCEAN group meeting. <i>Ocular Surface</i> , 2017, 15, 169-178.	2.2	57
23	Semifluorinated Alkane Eye Drops for Treatment of Dry Eye Disease Due to Meibomian Gland Disease. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2017, 33, 678-685.	0.6	42
24	Matrix Metalloproteinase 9 Testing in Dry Eye Disease Using a Commercially Available Point-of-Care Immunoassay. <i>Ophthalmology</i> , 2016, 123, 2300-2308.	2.5	123
25	Revisiting the vicious circle of dry eye disease: a focus on the pathophysiology of meibomian gland dysfunction. <i>British Journal of Ophthalmology</i> , 2016, 100, 300-306.	2.1	332
26	The Pathophysiology, Diagnosis, and Treatment of Dry Eye Disease. <i>Deutsches A&#x0308;rztblatt International</i> , 2015, 112, 71-81; quiz 82.	0.6	300
27	Prospective, randomized, double-blind trial to investigate the efficacy and safety of corneal cross-linking to halt the progression of keratoconus. <i>BMC Ophthalmology</i> , 2015, 15, 78.	0.6	47
28	<i>Cornea</i> , 2015, , 79-154.		4
29	Perioperative and postoperative risk factors for corneal graft failure. <i>Clinical Ophthalmology</i> , 2014, 8, 1641.	0.9	18
30	Donor-Related Risk Factors and Preoperative Recipient-Related Risk Factors for Graft Failure. <i>Cornea</i> , 2014, 33, 1149-1156.	0.9	36
31	Correlations between commonly used objective signs and symptoms for the diagnosis of dry eye disease: clinical implications. <i>Acta Ophthalmologica</i> , 2014, 92, 161-166.	0.6	280
32	Role of Hyperosmolarity in the Pathogenesis and Management of Dry Eye Disease: Proceedings of the OCEAN Group Meeting. <i>Ocular Surface</i> , 2013, 11, 246-258.	2.2	359
33	Update on corneal cross-linking for keratoconus. <i>Oman Journal of Ophthalmology</i> , 2013, 6, 8.	0.2	3
34	Morphological and Immunohistochemical Changes After Corneal Cross-Linking. <i>Cornea</i> , 2013, 32, 111-117.	0.9	58
35	Conjunctival Granulomatosis in Churg-Strauss Syndrome. <i>JAMA Ophthalmology</i> , 2012, 130, 1228.	2.6	3
36	Distribution of Antigen Presenting Cells in the Human Cornea: Correlation of In Vivo Confocal Microscopy and Immunohistochemistry in Different Pathologic Entities. <i>Current Eye Research</i> , 2012, 37, 1012-1018.	0.7	78

#	ARTICLE	IF	CITATIONS
37	Differences in basement membrane zone components of normal conjunctiva, conjunctiva in glaucoma and normal skin. <i>Acta Ophthalmologica</i> , 2012, 90, e476-81.	0.6	4
38	Expression of matrix metalloproteinase-1, -9, -13, and tissue inhibitor of metalloproteinases-1 in basal cell carcinomas of the eyelid. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2012, 250, 425-431.	1.0	9
39	In vivo confocal microscopy of corneal small fiber damage in diabetes mellitus. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2010, 248, 1307-1312.	1.0	101
40	Confocal microscopy: when is it helpful to diagnose corneal and conjunctival disease?. <i>Expert Review of Ophthalmology</i> , 2008, 3, 177-192.	0.3	6
41	In Vivo Confocal Microscopy in Healthy Conjunctiva, Conjunctivitis, and Conjunctival Tumors. , 2008, , 217-227.		0
42	In Vivo Confocal Microscopy of Filtering Blebs After Trabeculectomy. <i>JAMA Ophthalmology</i> , 2006, 124, 1095.	2.6	83
43	In Vivo Confocal Microscopy of Normal Conjunctiva and Conjunctivitis. <i>Cornea</i> , 2006, 25, 781-788.	0.9	95
44	In vivo confocal microscopy of pigmented conjunctival tumors. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2006, 244, 1437-1445.	1.0	51
45	Bilateral Recurrent Calcareous Degeneration of the Cornea. <i>Cornea</i> , 2005, 24, 498-502.	0.9	7
46	Toxic eosinophil granule protein deposition in corneal ulcerations and scars associated with atopic keratoconjunctivitis. <i>American Journal of Ophthalmology</i> , 2002, 134, 816-821.	1.7	50
47	Vasculitic Peripheral Ulcerative Keratitis. <i>Survey of Ophthalmology</i> , 1999, 43, 379-396.	1.7	191